Restricted accessResearch articleFirst published online 2016-6
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant
To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation.
Methods
In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell transplantation regimens who received a one-time dose of 150 mg IV fosaprepitant (n = 56) were compared to a historical control (n = 70).
Results
The primary endpoint of no emesis from melphalan administration through five days afterward was 80% for the fosaprepitant group versus 66% in the control group (p = 0.068). Addition of fosaprepitant demonstrated significant improvement in emetic episodes per patient during the entire assessment period (p = 0.011) and days 1–5 after melphalan (p = 0.045). Fosaprepitant resulted in no substantial nausea during the entire assessment period in 37% of high-dose melphalan patients and 57% of BEAM patients.
Conclusions
Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.
BallenKKHeskethAMHeyesC. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplantation2001; 28: 1061–1066.
2.
DuquetteDAdamJ-PGouletD. Retrospective analysis of the efficacy of antiemetic prophylaxis in different preparative regimens for autologous and allogeneic bone marrow transplantation. Biol Blood Marrow Transplantation2011; 17: 355–355.
3.
MussoMScaloneRCrescimannoA. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplantation2010; 45: 123–127.
4.
GiraltSAManganKFMaziarzRT. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol2011; 22: 939–946.
5.
HeskethPJ. Chemotherapy-induced nausea and vomiting. New Eng J Med2008; 358: 2482–2494.
Lopez-JimenezJMartin-BallesterosESuredaA. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica2006; 91: 84–91.
8.
Fox-GeimanMPFisherSGKileyK. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplantation2001; 7: 596–603.
9.
TriggMEInversoDM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplantation2008; 42: 501–506.
10.
KimDHJamalNSaragosaR. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplantation2007; 13: 1233–1243.
11.
RoilaFHerrstedtJAaproM. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol2010; 21(Suppl 5): v232–v243.
12.
BaschEPrestrudAAHeskethPJ. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol2011; 29: 4189–4198.
13.
SchmittTGoldschmidtHNebenK. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled Phase III trial. J Clin Oncol2014; 32: 3413–3420.
14.
StiffPJFox-GeimanMPKileyK. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplantation2013; 19: 49–55 e1.
15.
UchidaMKatoKIkesueH. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy2013; 33: 893–901.
16.
BubaloJSLeisJCurtinPT. A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol2007; 25: 9112–9112.
17.
JordanKJahnFJahnP. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplantation2011; 46: 784–789.
18.
PielichowskiWBarzalJGawronskiK. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplantation proceedings2011; 43: 3107–3110.
19.
PaulBTrovatoJAThompsonJ. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract2010; 16: 45–51.
20.
Deauna-LimayoDAljitawiOGangulyS. Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: a pilot study. J Oncol Pharm Pract2013; 20: 263–269.
21.
SakuraiMMoriTKatoJ. Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol2014; 99: 457–462.
22.
PielichowskiWGawronskiKMlotB. Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J BUON2011; 16: 541–546.
23.
SzerJGriggAPRobertsAWRaunowH. Aprepitant in the prevention of acute and delayed nausea and vomiting following hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplantation2006; 37: S112–S112.
24.
BechtelTMcBrideACrawfordB. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Supp Care Cancer2014; 22: 2911–2916.
25.
AugustinKMHladnikLDietzR. The efficacy of aprepitant added to ondansetron and dexamethasone for prevention of chemotherapy induced nausea and vomiting (CINV) during autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplantation2010; 16: 94–94.
26.
BarnettCMOholendtMPopatU. Evaluation of aprepitant for treatment of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing autologous stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2004; 104: 5041–5041.
27.
JohnstonJGregoryKChungH. Assessment of nausea and vomiting control with aprepitant in high-dose melphalan stem cell transplantation. Biol Blood Marrow Transplantation2014; 20: 451–451.
28.
GrunbergSChuaDMaruA. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol2011; 29: 1495–501.
29.
NachbaurDGreinixHTKollerE. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol2005; 84: 462–473.
30.
JagannathSVesoleDHGlennL. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood1992; 80: 1666–1672.
31.
BadrosABarlogieBSiegelE. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol2001; 114: 822–829.
LeesJMarottiR. Nausea and vomiting in bone marrow transplant (BMT) patients - an investigation of the incidence, timing, and related infections. Biol Blood Marrow Transplantation2006; 12: 502–502.
